ETAS® showed potential to suppress excessive inflammation induced by the SARS-CoV-2 spike proteins.
A paper on the study in collaboration with Dr. Ken Shirato from Department of Molecular Predictive Medicine and Sport Science, Kyorin University School of Medicine and Amino Up was published by Molecules （Molecules. 26(20):6189 (2021)）.
In this study, anti-inflammatory effect of ETAS® on macrophages stimulated by the SARS-CoV-2 spike protein S1 subunit (S1) focusing on excessive inflammation which increases severity of COVID-19. As a result, it was revealed that ETAS® suppresses excessive secretion of proinflammatory cytokines significantly by modulating inflammatory response of macrophages through p44/42 MAPK and Akt signaling pathway.
This result suggested potential of ETAS® to help people with high risks of developing severe symptoms of COVID-19 including ones with underlying diseases and the eldery.
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/34684771/